Contemporary antianginal pharmacotherapy: choosing the optimal solution to the problem

Posted on by adminLeave a comment

Prof. Korzh О.М.

Kharkiv National Medical University

The formation of antianginal pharmacotherapy has gone a long way, characterized by the search for the main factors of effective pharmacodynamics. The article presents an analysis of the use of drugs with different pharmacological properties in patients suffering from angina pectoris in a historical aspect, shows the evolution of researchers’ ideas about the mechanism of antianginal action, and gives a brief description of modern antianginal drugs. Analysis of the features of drug treatment of chronic coronary insufficiency with angina attacks gives reason to say that the development of pharmacology in this section of cardiology is in the direction of improvement, first of all, in the pharmacokinetic aspect of already known drugs.

Key words: antianginal drugs, angina pectoris, history of development, mechanism of action.

 https://doi.org/10.15407/internalmed2023.02.070

Download.PDF (ukr)

Cite:

  1. Корж, О.М. Сучасна антиангінальна фармакотерапія: вибір оптимального вирішення проблеми // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2023. – № 2. – С. 70-75 http://doi.org/10.15407/internalmed2023.02.070
  2. Korzh OM. [Contemporary antianginal pharmacotherapy: choosing the optimal solution to the problem]. Shidnoevr. z. vnutr. simejnoi med. 2023;2:70-75. Ukrainian. http://doi.org/10.15407/internalmed2023.02.070

References:

  1. Korzh OM. Diahnostyka i likuvannia stabilnoi ishemichnoi khvoroby sertsia v praktytsi simeinoho likaria. Skhidnoievropeiskyi zhurnal vnutrishnoi ta simeinoi medytsyny. 2019;2:63–68. Ukrainian
  2. Berger P. Ranolazine and Other Antianginal Therapies in the Era of the Drug-Eluting Stent. JAMA. 2004;291(3):365. http://dx.doi.org/10.1001/jama.291.3.365
  3. Knuuti J, Wijns W, Saraste A. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477. doi:10.1093/eurheartj/ehz425.
  4. Gricjuk AI. Lekarstvennye sredstva v klinicheskoj kardiologii. Kiev: Zdorov’e; 1977. 296 р. Russian
  5. Franchi F, Padeletti L. Evaluation of the clinical electrophysiological effects of antianginal drugs without specific antiarrhythmic properties. Methods Find Exp Clin Pharmacol. 1981;3(1):17–27.
  6. Kim H, Liao J. Translational Therapeutics of Dipyridamole. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28(3):. http://dx.doi.org/10.1161/atvbaha.107.160226
  7. Balakumar P, Nyo Y, Renushia R, Raaginey D, Oh A, Varatharajan R, Dhanaraj S. Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel?. Pharmacological Research. 2014;87:144-150. http://dx.doi.org/10.1016/j.phrs.2014.05.008
  8. Votchal BE. Ocherki klinicheskoj farmakologii. M.; 2007. 462 р. Russian
  9. Heger J, Prystowsky E, Miles W, Zipes D. Clinical Use and Pharmacology of Amiodarone. Medical Clinics of North America. 1984;68(5):1339-1366. http://dx.doi.org/10.1016/s0025-7125(16)31098-7
  10. Kaverina N, Markova G, Chichkanov G, Chumburidze V, Basaeva A. Nonachlasine — a new drug for treatment of ischemic heart disease. Kardiologiia. 1975;15(7):43–48.
  11. Mashkovskij MD. Lekarstvennye sredstva. M.; 1977. 1184 р. Russian
  12. Pavasini R, Camici P, Crea F, Danchin N, Fox K, Manolis A, Marzilli M, Rosano G, Lopez-Sendon J, Pinto F, Balla C, Ferrari R. Corrigendum to “Anti-anginal drugs: Systematic review and clinical implications” [Int. J. Cardiol. 283 (2019) 55–63]. International Journal of Cardiology. 2020;321:23. http://dx.doi.org/10.1016/j.ijcard.2020.06.028
  13. Rousan T, Mathew S, Thadani U. The risk of cardiovascular side effects with anti-anginal drugs. Expert Opinion on Drug Safety. 2016;15(12):1609-1623. http://dx.doi.org/10.1080/14740338.2016.1238457
  14. Bertero E, Heusch G, Münzel T, Maack C. A pathophysiological compass to personalize antianginal drug treatment. Nature Reviews Cardiology. 2021;18(12):838-852. http://dx.doi.org/10.1038/s41569-021-00573-w
  15. Ferratini M. Risk of rebound phenomenon during nitrate with drawal. International Journal of Cardiology. 1994;45(2):89-96. http://dx.doi.org/10.1016/0167-5273(94)90262-3
  16. Hwang D, Lee J, Kim H, Choi K, Rhee T, Park J, Park T, Yang J, Song Y, Choi J, Hahn J, Choi S, Koo B, Kim Y, Chae S, Cho M, Kim C, Gwon H, Jeong M, Kim H. Prognostic Impact of β-Blocker Dose After Acute Myocardial Infarction. Circulation Journal. 2019;83(2):410-417. http://dx.doi.org/10.1253/circj.cj-18-0662
  17. Tardif J, Ford I, Tendera M, Bourassa M, Fox K. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. European Heart Journal. 2005;26(23):2529-2536. http://dx.doi.org/10.1093/eurheartj/ehi586
  18. Ruzyllo W, Tendera M, Ford I, Fox K. Antianginal Efficacy and Safety of Ivabradine Compared with Amlodipine in Patients with Stable Effort Angina Pectoris. Drugs. 2007;67(3):393-405. http://dx.doi.org/10.2165/00003495-200767030-00005
  19. Jiang J, Li Y, Zhou Y, Li X, Li H, Tang B, Dai X, Ma T, Li L, Huo Y. Oral nicorandil reduces ischemic attacks in patients with stable angina: A prospective, multicenter, open-label, randomized, controlled study. International Journal of Cardiology. 2016;224:183-187. http://dx.doi.org/10.1016/j.ijcard.2016.08.305
  20. Sakamoto T, Kaikita K, Miyamoto S, Kojima S, Sugiyama S, Yoshimura M, Ogawa H. Effects of Nicorandil on Endogenous Fibrinolytic Capacity in Patients With Coronary Artery Disease. Circulation Journal. 2004;68(3):232-235. http://dx.doi.org/10.1253/circj.68.232
  21. Izumiya Y, Kojima S, Kojima S, Araki S, Usuku H, Matsubara J, Sakamoto K, Tsujita K, Nagayoshi Y, Kaikita K, Sugiyama S, Ogawa H. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. Atherosclerosis. 2011;214(2):415-421. http://dx.doi.org/10.1016/j.atherosclerosis.2010.11.032
  22. Rousseau M, Pouleur H, Cocco G, Wolff A. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. The American Journal of Cardiology. 2005;95(3):311-316. http://dx.doi.org/10.1016/j.amjcard.2004.09.025
  23. Manolis A, Kallistratos M, Poulimenos L, Zamfir T, Thomopoulos C. Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis. Hellenic Journal of Cardiology. 2023;71:26-32. http://dx.doi.org/10.1016/j.hjc.2022.12.002
  24. Arnold S, Kosiborod M, McGuire D, Li Y, Yue P, Ben-Yehuda O, Spertus J. Effects of Ranolazine on Quality of Life Among Patients With Diabetes Mellitus and Stable Angina. JAMA Internal Medicine. 2014;174(8):1403. http://dx.doi.org/10.1001/jamainternmed.2014.2120
  25. Peng S, Zhao M, Wan J, Fang Q, Fang D, Li K. The efficacy of trimetazidine on stable angina pectoris: A meta-analysis of randomized clinical trials. International Journal of Cardiology. 2014;177(3):780-785. http://dx.doi.org/10.1016/j.ijcard.2014.10.149
  26. Balla C, Pavasini R, Ferrari R. Treatment of Angina: Where Are We?. Cardiology. 2018;140(1):52-67. http://dx.doi.org/10.1159/000487936
  27. Belsey J, Savelieva I, Mugelli A, Camm A. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis. European Journal of Preventive Cardiology. 2014;22(7):837-848. http://dx.doi.org/10.1177/2047487314533217